Foghorn Therapeutics Inc.
FHTX
$5.41
-$0.12-2.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 26.97% | 108.40% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 26.97% | 108.40% | |||
| Cost of Revenue | 0.77% | 5.45% | |||
| Gross Profit | 9.18% | 11.21% | |||
| SG&A Expenses | -5.21% | 13.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.73% | 7.46% | |||
| Operating Income | 7.93% | 4.55% | |||
| Income Before Tax | 4.77% | 3.43% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 4.77% | 3.43% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 4.77% | 3.43% | |||
| EBIT | 7.93% | 4.55% | |||
| EBITDA | 8.33% | 4.98% | |||
| EPS Basic | 4.97% | 3.38% | |||
| Normalized Basic EPS | 4.97% | 3.40% | |||
| EPS Diluted | 4.97% | 3.38% | |||
| Normalized Diluted EPS | 4.97% | 3.40% | |||
| Average Basic Shares Outstanding | 0.21% | -0.04% | |||
| Average Diluted Shares Outstanding | 0.21% | -0.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||